Literature DB >> 22663954

A fatal outcome after unintentional overdosing of rivastigmine patches.

Henrik Lövborg1, Anna K Jönsson, Staffan Hägg.   

Abstract

BACKGROUND: Rivastigmine is an acetylcholine esterase inhibitor used in the treatment of dementia. Patches with rivastigmine for transdermal delivery have been used to increase compliance and to reduce side effects. CASE REPORT: We describe an 87-year old male with dementia treated with multiple rivastigmine patches (Exelon 9,5 mg/24 h) who developed nausea, vomiting and renal failure with disturbed electrolytes resulting in death. The symptoms occurred after six rivastigmine patches had concomitantly been erroneously applied by health care personnel on two consecutive days. The terminal cause of death was considered to be uremia from an acute tubular necrosis that was assessed as a result of dehydration through vomiting. The rivastigmine intoxication was assessed as having caused or contributed to the dehydrated condition. The medication error occurred at least partly due to ambiguous labeling. The clinical signs were not initially recognized as adverse effects of rivastigmine. DISCUSSION: The presented case is a description of a rivastigmine overdose due to a medication error involving patches. This case indicates the importance of clear and unambiguous instructions to avoid administration errors with patches and to be vigilant to adverse drug reactions for early detection and correction of drug administration errors. In particular, instructions clearly indicating that only one patch should be applied at a time are important.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22663954     DOI: 10.2174/157488612800492717

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  5 in total

1.  Safeguarding the process of drug administration with an emphasis on electronic support tools.

Authors:  Hanna M Seidling; Anette Lampert; Kristina Lohmann; Julia T Schiele; Alexander J F Send; Diana Witticke; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

2.  Unmet Needs for Transdermal Patch Management in Electronic Medication Administration Records: An Analysis of Data from 66 Aged Care Facilities.

Authors:  Magdalena Z Raban; Melissa T Baysari; Mikaela L Jorgensen; Amina Tariq; Andrew Georgiou; Johanna I Westbrook
Journal:  Appl Clin Inform       Date:  2020-12-09       Impact factor: 2.342

Review 3.  An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.

Authors:  Rita Khoury; Jayashree Rajamanickam; George T Grossberg
Journal:  Ther Adv Drug Saf       Date:  2018-01-08

4.  Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system.

Authors:  Henrik Lövborg; Mikael Holmlund; Staffan Hägg
Journal:  BMC Pharmacol Toxicol       Date:  2014-06-09       Impact factor: 2.483

5.  Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.

Authors:  Thibault B Ali; Thomas R Schleret; Brian M Reilly; Winston Yuchen Chen; Ruben Abagyan
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.